Publicacións en colaboración con investigadores/as de Clínica Universitaria de Navarra (27)

2022

  1. Heart failure in chronic kidney disease: The emerging role of myocardial fibrosis

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 5, pp. 817-824

2021

  1. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

    Nature Reviews Cardiology, Vol. 18, Núm. 7, pp. 479-498

  2. Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension

    JACC: Basic to Translational Science, Vol. 6, Núm. 1, pp. 12-21

2020

  1. Author Correction: MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure (Scientific Reports, (2017), 7, 1, (40696), 10.1038/srep40696)

    Scientific Reports

2019

  1. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) axis in cardiac fibrosis and inflammation: Mechanistic insights and clinical implications

    Hypertension, Vol. 73, Núm. 3, pp. 602-611

2017

  1. Hypertensive Heart Disease

    Encyclopedia of Cardiovascular Research and Medicine (Elsevier), pp. 517-526

  2. MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure

    Scientific Reports, Vol. 7

  3. Papel del colágeno miocárdico en la estenosis aórtica grave con fracción de eyección conservada y síntomas de insuficiencia cardiaca

    Revista Espanola de Cardiologia, Vol. 70, Núm. 10, pp. 832-840

  4. Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients ≥60 Years With Heart Failure and Reduced Ejection Fraction

    American Journal of Cardiology, Vol. 119, Núm. 12, pp. 2042-2048

2016

  1. Diastolic left ventricular function in relation to urinary and serum collagen biomarkers in a general population

    PLoS ONE, Vol. 11, Núm. 12

2015

  1. Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: A pilot study

    Free Radical Biology and Medicine, Vol. 81, pp. 1-12

  2. Circulating biomarkers of myocardial fibrosis: The need for a reappraisal

    Journal of the American College of Cardiology, Vol. 65, Núm. 22, pp. 2449-2456

  3. Diltiazem treatment for pre-Clinical hypertrophic cardiomyopathy sarcomereMutation carriers: A pilot randomized trial to modify disease expression

    JACC: Heart Failure, Vol. 3, Núm. 2, pp. 180-188

2014

  1. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure

    Hypertension, Vol. 63, Núm. 3, pp. 483-489

  2. microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation

    Clinical Science, Vol. 126, Núm. 7, pp. 497-506

2013

  1. Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients

    Journal of Hypertension, Vol. 31, Núm. 3, pp. 587-594

  2. Osteopontin-mediated myocardial fibrosis in heart failure: A role for lysyl oxidase?

    Cardiovascular Research, Vol. 99, Núm. 1, pp. 111-120

  3. The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus

    Cardiovascular Diabetology, Vol. 12, Núm. 1

2012

  1. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: Potential role of lysyl oxidase

    Hypertension, Vol. 60, Núm. 3, pp. 677-683

2011

  1. Association of the peroxisome proliferator-activated receptor α gene L162V polymorphism with stage C heart failure

    Journal of Hypertension, Vol. 29, Núm. 5, pp. 876-883